4
Changes in Ownership
Protalix BioTherapeutics, Inc. Filed Acc 0001385115-08-000001
VP, Chief Financial Officer sold 33,300 shares at $3.18 ($105,761)
- VP, Chief Financial Officer gave up 26,176 shares (to pay taxes)
- VP, Chief Financial Officer acquired 86,176 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Yossi Maimon VP, Chief Financial Officer | 2008-02-22 | Option exercise | +86,176 | $0.97 | $83,763 | 86,176 | I: show line 1 in the form |
| Yossi Maimon VP, Chief Financial Officer | 2008-02-22 | Shares withheld for taxes | −26,176 | $3.20 | $83,763 | 60,000 | I: show line 2 in the form |
| Yossi Maimon VP, Chief Financial Officer | 2008-02-25 | Sale | −33,300 | $3.18 | $105,761 | 26,700 | I: show line 3 in the form |
| Open-market sales · 33,300 sh · avg $3.18 · $105,761 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Yossi Maimon VP, Chief Financial Officer | 2008-02-22 | Option exercise · Stock Options (Right to Buy) | −86,176 | 533,796 | D: show line 4 in the form |
Loading xslF345X02/primary_doc.xml…